ImmuCell Corporation (ICCC)
USD 5.29
(-1.22%)
USD 5.29
(-1.22%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 9.61 Million USD | 1.97% |
| 2022 | 9.94 Million USD | 18.44% |
| 2021 | 8.39 Million USD | 1.89% |
| 2020 | 8.24 Million USD | 7.14% |
| 2019 | 7.69 Million USD | 4.81% |
| 2018 | 7.34 Million USD | 34.35% |
| 2017 | 5.46 Million USD | 20.61% |
| 2016 | 4.53 Million USD | 9.73% |
| 2015 | 4.12 Million USD | -11.32% |
| 2014 | 4.65 Million USD | 51.14% |
| 2013 | 3.08 Million USD | 9.64% |
| 2012 | 2.8 Million USD | -18.49% |
| 2011 | 3.44 Million USD | 15.16% |
| 2010 | 2.99 Million USD | 2.21% |
| 2009 | 2.92 Million USD | -9.69% |
| 2008 | 3.24 Million USD | 10.72% |
| 2007 | 2.92 Million USD | 36.31% |
| 2006 | 2.14 Million USD | -10.91% |
| 2005 | 2.41 Million USD | 13.39% |
| 2004 | 2.12 Million USD | -12.82% |
| 2003 | 2.43 Million USD | -14.48% |
| 2002 | 2.85 Million USD | 2.19% |
| 2001 | 2.79 Million USD | 9.26% |
| 2000 | 2.55 Million USD | 13.89% |
| 1999 | 2.24 Million USD | -13.74% |
| 1998 | 2.6 Million USD | 0.0% |
| 1997 | 2.6 Million USD | -3.7% |
| 1996 | 2.7 Million USD | -12.9% |
| 1995 | 3.1 Million USD | 6.9% |
| 1994 | 2.9 Million USD | 26.09% |
| 1993 | 2.3 Million USD | 15.0% |
| 1992 | 2 Million USD | -13.04% |
| 1991 | 2.3 Million USD | -4.17% |
| 1990 | 2.4 Million USD | 9.09% |
| 1989 | 2.2 Million USD | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q1 | 2.59 Million USD | 14.79% |
| 2024 Q2 | 2.61 Million USD | 0.84% |
| 2023 Q3 | 2.45 Million USD | 4.37% |
| 2023 FY | 9.61 Million USD | -3.32% |
| 2023 Q2 | 2.34 Million USD | -8.15% |
| 2023 Q1 | 2.55 Million USD | -2.64% |
| 2023 Q4 | 2.26 Million USD | -7.75% |
| 2022 FY | 9.94 Million USD | 18.44% |
| 2022 Q4 | 2.62 Million USD | 6.63% |
| 2022 Q1 | 2.31 Million USD | -4.37% |
| 2022 Q2 | 2.32 Million USD | 0.7% |
| 2022 Q3 | 2.46 Million USD | 5.87% |
| 2021 Q4 | 2.41 Million USD | 12.49% |
| 2021 Q3 | 2.14 Million USD | 15.54% |
| 2021 Q2 | 1.85 Million USD | -5.97% |
| 2021 FY | 8.39 Million USD | 1.89% |
| 2021 Q1 | 1.97 Million USD | -12.34% |
| 2020 Q2 | 1.97 Million USD | -3.17% |
| 2020 Q4 | 2.25 Million USD | 14.23% |
| 2020 FY | 8.24 Million USD | 7.14% |
| 2020 Q3 | 1.97 Million USD | -0.02% |
| 2020 Q1 | 2.03 Million USD | -1.96% |
| 2019 Q1 | 1.93 Million USD | -16.62% |
| 2019 FY | 7.69 Million USD | 4.81% |
| 2019 Q2 | 1.79 Million USD | -7.24% |
| 2019 Q3 | 1.88 Million USD | 4.74% |
| 2019 Q4 | 2.08 Million USD | 10.57% |
| 2018 Q4 | 2.32 Million USD | 28.99% |
| 2018 Q3 | 1.8 Million USD | 7.13% |
| 2018 Q2 | 1.68 Million USD | 9.26% |
| 2018 Q1 | 1.53 Million USD | -5.36% |
| 2018 FY | 7.34 Million USD | 34.35% |
| 2017 Q1 | 1.23 Million USD | 12.22% |
| 2017 FY | 5.46 Million USD | 20.61% |
| 2017 Q4 | 1.62 Million USD | 14.58% |
| 2017 Q3 | 1.41 Million USD | 19.52% |
| 2017 Q2 | 1.18 Million USD | -3.81% |
| 2016 Q1 | 1.05 Million USD | -11.49% |
| 2016 FY | 4.53 Million USD | 9.73% |
| 2016 Q4 | 1.09 Million USD | -4.75% |
| 2016 Q3 | 1.15 Million USD | -5.27% |
| 2016 Q2 | 1.21 Million USD | 15.1% |
| 2015 Q4 | 1.19 Million USD | 21.42% |
| 2015 FY | 4.12 Million USD | -11.32% |
| 2015 Q1 | 1.03 Million USD | -9.88% |
| 2015 Q3 | 985.05 Thousand USD | 7.47% |
| 2015 Q2 | 916.59 Thousand USD | -11.09% |
| 2014 Q2 | 1.33 Million USD | 17.57% |
| 2014 FY | 4.65 Million USD | 51.14% |
| 2014 Q4 | 1.14 Million USD | 10.3% |
| 2014 Q3 | 1.03 Million USD | -22.45% |
| 2014 Q1 | 1.13 Million USD | 39.1% |
| 2013 Q4 | 817.61 Thousand USD | 5.41% |
| 2013 Q1 | 726.9 Thousand USD | -1.47% |
| 2013 Q2 | 759.95 Thousand USD | 4.55% |
| 2013 FY | 3.08 Million USD | 9.64% |
| 2013 Q3 | 775.68 Thousand USD | 2.07% |
| 2012 FY | 2.8 Million USD | -18.49% |
| 2012 Q4 | 737.71 Thousand USD | 4.33% |
| 2012 Q3 | 707.08 Thousand USD | 11.68% |
| 2012 Q2 | 633.12 Thousand USD | -13.43% |
| 2012 Q1 | 731.33 Thousand USD | 2.19% |
| 2011 Q2 | 1.12 Million USD | 27.37% |
| 2011 Q1 | 885.09 Thousand USD | 9.52% |
| 2011 Q3 | 718.42 Thousand USD | -36.28% |
| 2011 Q4 | 715.62 Thousand USD | -0.39% |
| 2011 FY | 3.44 Million USD | 15.16% |
| 2010 FY | 2.99 Million USD | 2.21% |
| 2010 Q1 | 813.55 Thousand USD | 17.69% |
| 2010 Q2 | 666.24 Thousand USD | -18.11% |
| 2010 Q3 | 704.81 Thousand USD | 5.79% |
| 2010 Q4 | 808.14 Thousand USD | 14.66% |
| 2009 Q2 | 804.32 Thousand USD | 1.27% |
| 2009 Q1 | 794.23 Thousand USD | -7.93% |
| 2009 Q4 | 691.27 Thousand USD | 8.32% |
| 2009 FY | 2.92 Million USD | -9.69% |
| 2009 Q3 | 638.16 Thousand USD | -20.66% |
| 2008 Q3 | 852.38 Thousand USD | 10.08% |
| 2008 Q4 | 862.63 Thousand USD | 1.2% |
| 2008 FY | 3.24 Million USD | 10.72% |
| 2008 Q1 | 752.85 Thousand USD | -5.26% |
| 2008 Q2 | 774.36 Thousand USD | 2.86% |
| 2007 Q1 | 614.64 Thousand USD | 7.19% |
| 2007 Q2 | 600.92 Thousand USD | -2.23% |
| 2007 Q4 | 794.64 Thousand USD | -13.44% |
| 2007 Q3 | 918.05 Thousand USD | 52.77% |
| 2007 FY | 2.92 Million USD | 36.31% |
| 2006 Q2 | 487.3 Thousand USD | -15.75% |
| 2006 Q4 | 573.44 Thousand USD | 12.64% |
| 2006 Q3 | 509.07 Thousand USD | 4.47% |
| 2006 Q1 | 578.4 Thousand USD | -8.81% |
| 2006 FY | 2.14 Million USD | -10.91% |
| 2005 Q3 | 624.03 Thousand USD | 17.45% |
| 2005 Q4 | 634.3 Thousand USD | 1.64% |
| 2005 Q2 | 531.3 Thousand USD | -14.52% |
| 2005 FY | 2.41 Million USD | 13.39% |
| 2005 Q1 | 621.52 Thousand USD | -0.63% |
| 2004 FY | 2.12 Million USD | -12.82% |
| 2004 Q1 | 502.67 Thousand USD | -31.78% |
| 2004 Q2 | 475.64 Thousand USD | -5.38% |
| 2004 Q3 | 522.73 Thousand USD | 9.9% |
| 2004 Q4 | 625.44 Thousand USD | 19.65% |
| 2003 Q2 | 546.29 Thousand USD | 0.94% |
| 2003 FY | 2.43 Million USD | -14.48% |
| 2003 Q4 | 736.79 Thousand USD | 40.86% |
| 2003 Q3 | 523.06 Thousand USD | -4.25% |
| 2003 Q1 | 541.18 Thousand USD | -22.1% |
| 2002 FY | 2.85 Million USD | 2.19% |
| 2002 Q4 | 694.73 Thousand USD | 4.28% |
| 2002 Q3 | 666.24 Thousand USD | -10.5% |
| 2002 Q2 | 744.42 Thousand USD | -0.31% |
| 2002 Q1 | 746.73 Thousand USD | -14.2% |
| 2001 Q3 | 651.41 Thousand USD | -2.69% |
| 2001 Q4 | 870.34 Thousand USD | 33.61% |
| 2001 Q2 | 669.39 Thousand USD | 5.61% |
| 2001 Q1 | 633.86 Thousand USD | 2.89% |
| 2001 FY | 2.79 Million USD | 9.26% |
| 2000 FY | 2.55 Million USD | 13.89% |
| 2000 Q4 | 616.04 Thousand USD | -2.99% |
| 2000 Q3 | 635.02 Thousand USD | -11.16% |
| 2000 Q2 | 714.79 Thousand USD | 21.46% |
| 2000 Q1 | 588.5 Thousand USD | -8.45% |
| 1999 FY | 2.24 Million USD | -13.74% |
| 1999 Q3 | 500 Thousand USD | -16.67% |
| 1999 Q4 | 642.85 Thousand USD | 28.57% |
| 1999 Q1 | 500 Thousand USD | -28.57% |
| 1999 Q2 | 600 Thousand USD | 20.0% |
| 1998 Q1 | 600 Thousand USD | -14.29% |
| 1998 FY | 2.6 Million USD | 0.0% |
| 1998 Q4 | 700 Thousand USD | 16.67% |
| 1998 Q3 | 600 Thousand USD | 0.0% |
| 1998 Q2 | 600 Thousand USD | 0.0% |
| 1997 Q3 | 700 Thousand USD | 16.67% |
| 1997 Q4 | 700 Thousand USD | 0.0% |
| 1997 FY | 2.6 Million USD | -3.7% |
| 1997 Q1 | 600 Thousand USD | 20.0% |
| 1997 Q2 | 600 Thousand USD | 0.0% |
| 1996 FY | 2.7 Million USD | -12.9% |
| 1996 Q4 | 500 Thousand USD | -28.57% |
| 1996 Q3 | 700 Thousand USD | 16.67% |
| 1996 Q2 | 600 Thousand USD | -33.33% |
| 1996 Q1 | 900 Thousand USD | 28.57% |
| 1995 FY | 3.1 Million USD | 6.9% |
| 1995 Q4 | 700 Thousand USD | -12.5% |
| 1995 Q3 | 800 Thousand USD | -11.11% |
| 1995 Q2 | 900 Thousand USD | 12.5% |
| 1995 Q1 | 800 Thousand USD | 0.0% |
| 1994 Q2 | 600 Thousand USD | 20.0% |
| 1994 Q4 | 800 Thousand USD | 14.29% |
| 1994 FY | 2.9 Million USD | 26.09% |
| 1994 Q1 | 500 Thousand USD | -58.33% |
| 1994 Q3 | 700 Thousand USD | 16.67% |
| 1993 Q3 | 300 Thousand USD | -40.0% |
| 1993 Q4 | 1.2 Million USD | 300.0% |
| 1993 Q2 | 500 Thousand USD | -16.67% |
| 1993 Q1 | 600 Thousand USD | 20.0% |
| 1993 FY | 2.3 Million USD | 15.0% |
| 1992 Q3 | 500 Thousand USD | 25.0% |
| 1992 Q2 | 400 Thousand USD | -20.0% |
| 1992 FY | 2 Million USD | -13.04% |
| 1992 Q4 | 500 Thousand USD | 0.0% |
| 1992 Q1 | 500 Thousand USD | 0.0% |
| 1991 Q1 | 500 Thousand USD | -61.54% |
| 1991 FY | 2.3 Million USD | -4.17% |
| 1991 Q4 | 500 Thousand USD | -28.57% |
| 1991 Q3 | 700 Thousand USD | 133.33% |
| 1991 Q2 | 300 Thousand USD | -40.0% |
| 1990 Q1 | 600 Thousand USD | -25.0% |
| 1990 FY | 2.4 Million USD | 9.09% |
| 1990 Q3 | 300 Thousand USD | 0.0% |
| 1990 Q4 | 1.3 Million USD | 333.33% |
| 1990 Q2 | 300 Thousand USD | -50.0% |
| 1989 Q1 | - USD | 0.0% |
| 1989 FY | 2.2 Million USD | 0.0% |
| 1989 Q3 | 400 Thousand USD | -20.0% |
| 1989 Q4 | 800 Thousand USD | 100.0% |
| 1989 Q2 | 500 Thousand USD | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| AbCellera Biologics Inc. | 275.23 Million USD | 96.506% |
| Alkermes plc | 996.24 Million USD | 99.035% |
| Agenus Inc. | 78.18 Million USD | 87.699% |
| Aptorum Group Limited | 10.56 Thousand USD | -90921.787% |
| Ardelyx, Inc. | 169.93 Million USD | 94.341% |
| Dyadic International, Inc. | 9.15 Million USD | -5.077% |
| Eton Pharmaceuticals, Inc. | 22.25 Million USD | 56.782% |
| Lantern Pharma Inc. | 17.87 Million USD | 46.204% |
| Inhibikase Therapeutics, Inc. | 6.73 Million USD | -42.862% |
| Novavax, Inc. | 779.12 Million USD | 98.766% |
| Janux Therapeutics, Inc. | 81.06 Million USD | 88.136% |
| Pyxis Oncology, Inc. | 82.19 Million USD | 88.299% |
| TransCode Therapeutics, Inc. | 19.41 Million USD | 50.473% |
| Ocuphire Pharma, Inc. | 29.6 Million USD | 67.515% |
| Outlook Therapeutics, Inc. | 53.12 Million USD | 81.897% |
| Madrigal Pharmaceuticals, Inc. | 380.49 Million USD | 97.472% |
| Reviva Pharmaceuticals Holdings, Inc. | 24.3 Million USD | 60.433% |
| SELLAS Life Sciences Group, Inc. | 37.86 Million USD | 74.604% |
| Syros Pharmaceuticals, Inc. | 30.77 Million USD | 68.745% |
| Barinthus Biotherapeutics plc | 84.71 Million USD | 88.648% |
| Windtree Therapeutics, Inc. | 17.45 Million USD | 44.908% |
| Xeris Biopharma Holdings, Inc. | 168.43 Million USD | 94.29% |
| Clearside Biomedical, Inc. | 32.71 Million USD | 70.603% |
| C4 Therapeutics, Inc. | 159.78 Million USD | 93.981% |
| Alnylam Pharmaceuticals, Inc. | 1.8 Billion USD | 99.466% |
| AlloVir, Inc. | 180.93 Million USD | 94.685% |
| Arrowhead Pharmaceuticals, Inc. | 445.73 Million USD | 97.842% |
| VYNE Therapeutics Inc. | 29.68 Million USD | 67.599% |
| Bicycle Therapeutics plc | 216.92 Million USD | 95.566% |
| BioXcel Therapeutics, Inc. | 171.9 Million USD | 94.405% |
| ChromaDex Corporation | 56.37 Million USD | 82.942% |
| Chimerix, Inc. | 93.38 Million USD | 89.702% |
| Corbus Pharmaceuticals Holdings, Inc. | 13.9 Million USD | 30.858% |
| Caribou Biosciences, Inc. | 150.53 Million USD | 93.611% |
| CRISPR Therapeutics AG | 463.49 Million USD | 97.925% |
| Precision BioSciences, Inc. | 92.46 Million USD | 89.599% |
| Fate Therapeutics, Inc. | 254.04 Million USD | 96.214% |
| Fortress Biotech, Inc. | 200.19 Million USD | 95.196% |
| Fortress Biotech, Inc. | 200.19 Million USD | 95.196% |
| HOOKIPA Pharma Inc. | 32.74 Million USD | 70.63% |
| IDEAYA Biosciences, Inc. | 157.81 Million USD | 93.906% |
| Immix Biopharma, Inc. | 16.14 Million USD | 40.417% |
| Incyte Corporation | 1.19 Billion USD | 99.192% |
| Innoviva, Inc. | 132.15 Million USD | 92.723% |
| IO Biotech, Inc. | 91.44 Million USD | 89.483% |
| Jaguar Health, Inc. | 42.01 Million USD | 77.11% |
| Keros Therapeutics, Inc. | 169.27 Million USD | 94.319% |
| Ligand Pharmaceuticals Incorporated | 84.32 Million USD | 88.595% |
| ContextLogic Inc. | 387 Million USD | 97.515% |
| MiMedx Group, Inc. | 229.72 Million USD | 95.814% |
| MEI Pharma, Inc. | 34.78 Million USD | 72.352% |
| NextCure, Inc. | 67.63 Million USD | 85.781% |
| Onconetix, Inc. | 34.9 Million USD | 72.449% |
| Oncternal Therapeutics, Inc. | 12.74 Million USD | 24.546% |
| Opthea Limited | 191.96 Million USD | 94.99% |
| Psyence Biomedical Ltd. | 2.75 Million USD | -249.521% |
| Vaxcyte, Inc. | 468.04 Million USD | 97.945% |
| PDS Biotechnology Corporation | 43.04 Million USD | 77.658% |
| Precigen, Inc. | 84.18 Million USD | 88.575% |
| Pharming Group N.V. | 225.49 Million USD | 95.735% |
| Phathom Pharmaceuticals, Inc. | 167.82 Million USD | 94.269% |
| Pieris Pharmaceuticals, Inc. | 72.56 Million USD | 86.747% |
| PureTech Health plc | 144.59 Million USD | 93.349% |
| Rigel Pharmaceuticals, Inc. | 130.26 Million USD | 92.617% |
| Avidity Biosciences, Inc. | 245.15 Million USD | 96.077% |
| Reviva Pharmaceuticals Holdings, Inc. | 24.3 Million USD | 60.433% |
| Sangamo Therapeutics, Inc. | 228.68 Million USD | 95.794% |
| Sol-Gel Technologies Ltd. | 30.85 Million USD | 68.834% |
| Acelyrin, Inc. | 422.06 Million USD | 97.721% |
| Salarius Pharmaceuticals, Inc. | 12.89 Thousand USD | -74487.886% |
| Summit Therapeutics Inc. | 87.68 Million USD | 89.032% |
| Sensei Biotherapeutics, Inc. | 37.06 Million USD | 74.052% |
| Senti Biosciences, Inc. | 94.7 Million USD | 89.845% |
| Stoke Therapeutics, Inc. | 123.55 Million USD | 92.216% |
| Elevation Oncology, Inc. | 45.44 Million USD | 78.837% |
| Alaunos Therapeutics, Inc. | 29.46 Million USD | 67.364% |
| Telomir Pharmaceuticals, Inc. Common Stock | 3.94 Million USD | -143.969% |
| Entrada Therapeutics, Inc. | 132.17 Million USD | 92.724% |
| VistaGen Therapeutics, Inc. | 34.08 Million USD | 71.784% |
| Kintara Therapeutics, Inc. | 8.45 Million USD | -13.801% |
| Wave Life Sciences Ltd. | 181.3 Million USD | 94.695% |
| Seer, Inc. | 110.49 Million USD | 91.296% |
| Verrica Pharmaceuticals Inc. | 70.59 Million USD | 86.377% |
| Aadi Bioscience, Inc. | 93.47 Million USD | 89.712% |
| ESSA Pharma Inc. | 32.13 Million USD | 70.071% |
| GlycoMimetics, Inc. | 39.28 Million USD | 75.519% |
| GT Biopharma, Inc. | 13.57 Million USD | 29.159% |
| Inhibrx Biosciences, Inc. | 219.83 Million USD | 95.625% |
| Akebia Therapeutics, Inc. | 201.11 Million USD | 95.218% |
| Catalyst Pharmaceuticals, Inc. | 259.42 Million USD | 96.293% |
| Longboard Pharmaceuticals, Inc. | 56.75 Million USD | 83.056% |
| Orchestra BioMed Holdings, Inc. | 54.08 Million USD | 82.216% |
| Alzamend Neuro, Inc. | 9.93 Million USD | 3.223% |
| Sorrento Therapeutics, Inc. | 403.56 Million USD | 97.617% |
| TRACON Pharmaceuticals, Inc. | 18.92 Million USD | 49.192% |
| Viracta Therapeutics, Inc. | 50.69 Million USD | 81.028% |
| Rocket Pharmaceuticals, Inc. | 259.65 Million USD | 96.296% |
| Aptose Biosciences Inc. | 52.35 Million USD | 81.631% |
| ZyVersa Therapeutics, Inc. | 14.41 Million USD | 33.261% |
| Soligenix, Inc. | 7.79 Million USD | -23.375% |
| Century Therapeutics, Inc. | 56.07 Million USD | 82.848% |
| Kura Oncology, Inc. | 165.8 Million USD | 94.2% |
| TScan Therapeutics, Inc. | 114.5 Million USD | 91.601% |
| Intensity Therapeutics, Inc. | 8.31 Million USD | -15.607% |
| Ocean Biomedical, Inc. | 2.48 Million USD | -287.541% |
| CytomX Therapeutics, Inc. | 107.69 Million USD | 91.07% |
| Autolus Therapeutics plc | 196.72 Million USD | 95.111% |
| Mineralys Therapeutics, Inc. | 84.65 Million USD | 88.64% |
| EyePoint Pharmaceuticals, Inc. | 116.45 Million USD | 91.741% |
| Eterna Therapeutics Inc. | 19.38 Million USD | 50.382% |
| Adaptive Biotechnologies Corporation | 321.75 Million USD | 97.011% |
| GRI Bio, Inc. | 11.33 Million USD | 15.116% |
| Xenetic Biosciences, Inc. | 7.05 Million USD | -36.306% |
| Tenaya Therapeutics, Inc. | 131.19 Million USD | 92.669% |
| IGM Biosciences, Inc. | 265.59 Million USD | 96.379% |
| INmune Bio, Inc. | 29.89 Million USD | 67.831% |
| Heron Therapeutics, Inc. | 172.55 Million USD | 94.426% |
| SAB Biotherapeutics, Inc. | 40.31 Million USD | 76.144% |
| Pasithea Therapeutics Corp. | 15.97 Million USD | 39.814% |
| Entero Therapeutics, Inc. | 15.74 Million USD | 38.905% |
| Milestone Pharmaceuticals Inc. | 62.09 Million USD | 84.513% |
| X4 Pharmaceuticals, Inc. | 107.52 Million USD | 91.055% |
| Atara Biotherapeutics, Inc. | 275.69 Million USD | 96.512% |
| Coherus BioSciences, Inc. | 301.45 Million USD | 96.81% |
| Verastem, Inc. | 92.08 Million USD | 89.556% |
| Abeona Therapeutics Inc. | 17.93 Million USD | 46.389% |
| Pliant Therapeutics, Inc. | 185.72 Million USD | 94.822% |
| Tonix Pharmaceuticals Holding Corp. | 121.4 Million USD | 92.078% |
| Histogen Inc. | 14.27 Million USD | 32.614% |
| Aprea Therapeutics, Inc. | 16.04 Million USD | 40.072% |
| Surrozen, Inc. | 18.55 Million USD | 48.154% |
| Organovo Holdings, Inc. | 14.91 Million USD | 35.519% |
| Lixte Biotechnology Holdings, Inc. | 5.09 Million USD | -88.937% |
| Ovid Therapeutics Inc. | 59.67 Million USD | 83.883% |
| Panbela Therapeutics, Inc. | 25.64 Million USD | 62.501% |
| CASI Pharmaceuticals, Inc. | 47 Million USD | 79.54% |
| Cadrenal Therapeutics, Inc. Common Stock | 7.63 Million USD | -26.0% |
| Centessa Pharmaceuticals plc | 178.13 Million USD | 94.601% |
| Hepion Pharmaceuticals, Inc. | 48.44 Million USD | 80.149% |
| Arcturus Therapeutics Holdings Inc. | 245 Million USD | 96.075% |
| BioRestorative Therapies, Inc. | 15.36 Million USD | 37.414% |
| Apollomics, Inc. | 54.14 Million USD | 82.236% |
| Amarin Corporation plc | 272.35 Million USD | 96.469% |
| Mesoblast Limited | 5.9 Million USD | -62.951% |
| Turnstone Biologics Corp. | 78.33 Million USD | 87.723% |
| Kymera Therapeutics, Inc. | 244.12 Million USD | 96.06% |
| Synaptogenix, Inc. | 8.31 Million USD | -15.679% |
| Tiziana Life Sciences Ltd | 14.58 Million USD | 34.064% |
| Aurinia Pharmaceuticals Inc. | 253.05 Million USD | 96.2% |
| BriaCell Therapeutics Corp. | 33.33 Million USD | 71.145% |
| Monopar Therapeutics Inc. | 8.83 Million USD | -8.902% |
| Exelixis, Inc. | 1.58 Billion USD | 99.394% |
| Better Therapeutics, Inc. | 38.26 Million USD | 74.864% |
| Nurix Therapeutics, Inc. | 232.05 Million USD | 95.855% |
| Apellis Pharmaceuticals, Inc. | 855.2 Million USD | 98.875% |
| NLS Pharmaceutics AG | 11.8 Million USD | 18.546% |
| Dermata Therapeutics, Inc. | 8.04 Million USD | -19.591% |
| Aridis Pharmaceuticals, Inc. | 29.99 Million USD | 67.935% |
| Gritstone bio, Inc. | 148.37 Million USD | 93.518% |
| Jasper Therapeutics, Inc. | 68.86 Million USD | 86.034% |
| TNF Pharmaceuticals, Inc. | 16.36 Million USD | 41.215% |
| Avid Bioservices, Inc. | 25.99 Million USD | 63.004% |
| Insmed Incorporated | 949.26 Million USD | 98.987% |
| Virpax Pharmaceuticals, Inc. | 15.68 Million USD | 38.703% |
| MediWound Ltd. | 18.86 Million USD | 49.028% |
| OmniAb, Inc. | 83.89 Million USD | 88.536% |
| Alector, Inc. | 248.8 Million USD | 96.135% |
| Seres Therapeutics, Inc. | 234.3 Million USD | 95.895% |
| Checkpoint Therapeutics, Inc. | 52.25 Million USD | 81.594% |
| Zai Lab Limited | 547.47 Million USD | 98.243% |
| Revance Therapeutics, Inc. | 398.65 Million USD | 97.588% |
| Aura Biosciences, Inc. | 84.99 Million USD | 88.684% |
| Lyell Immunopharma, Inc. | 247.13 Million USD | 96.109% |
| Immunic, Inc. | 99.22 Million USD | 90.307% |
| Tarsus Pharmaceuticals, Inc. | 159.01 Million USD | 93.952% |
| Veracyte, Inc. | 357.93 Million USD | 97.313% |
| InMed Pharmaceuticals Inc. | 9.01 Billion USD | 99.893% |
| FibroGen, Inc. | 398.11 Million USD | 97.584% |
| SeaStar Medical Holding Corporation | 14.21 Million USD | 32.32% |
| Adial Pharmaceuticals, Inc. | 6.88 Million USD | -39.626% |
| Sonnet BioTherapeutics Holdings, Inc. | 7.12 Million USD | -34.967% |
| Jazz Pharmaceuticals plc | 3.25 Billion USD | 99.705% |
| Cyclacel Pharmaceuticals, Inc. | 25.87 Million USD | 62.829% |
| Amylyx Pharmaceuticals, Inc. | 316.54 Million USD | 96.962% |
| TG Therapeutics, Inc. | 198.47 Million USD | 95.154% |
| Galecto, Inc. | 35.62 Million USD | 73.005% |
| Calithera Biosciences, Inc. | 40.68 Million USD | 76.364% |
| Fortrea Holdings Inc. | 457.3 Million USD | 97.897% |
| KalVista Pharmaceuticals, Inc. | 54.27 Million USD | 82.281% |
| Aptevo Therapeutics Inc. | 28.87 Million USD | 66.697% |
| XBiotech Inc. | 37.51 Million USD | 74.361% |
| Jasper Therapeutics, Inc. | 68.86 Million USD | 86.034% |
| Lyra Therapeutics, Inc. | 20.64 Million USD | 53.425% |
| Foghorn Therapeutics Inc. | 142.06 Million USD | 93.23% |
| Y-mAbs Therapeutics, Inc. | 99.07 Million USD | 90.293% |
| Theravance Biopharma, Inc. | 110.71 Million USD | 91.313% |
| Ultragenyx Pharmaceutical Inc. | 958.24 Million USD | 98.996% |
| Metagenomi, Inc. Common Stock | 28.84 Million USD | 66.658% |
| Vaxxinity, Inc. | 56.05 Million USD | 82.842% |
| BioCryst Pharmaceuticals, Inc. | 430.64 Million USD | 97.767% |
| Gain Therapeutics, Inc. | 22.3 Million USD | 56.889% |
| Cartesian Therapeutics, Inc. | 110.86 Million USD | 91.325% |
| NexImmune, Inc. | 28.16 Million USD | 65.857% |
| Creative Medical Technology Holdings, Inc. | 5.53 Million USD | -73.883% |
| Marker Therapeutics, Inc. | 17.89 Million USD | 46.249% |
| Regeneron Pharmaceuticals, Inc. | 2.81 Billion USD | 99.658% |
| Chemomab Therapeutics Ltd. | 25.45 Million USD | 62.224% |
| Scopus BioPharma Inc. | 11.71 Million USD | 17.905% |
| RAPT Therapeutics, Inc. | 127.06 Million USD | 92.431% |
| Ainos, Inc. | 12.95 Million USD | 25.75% |
| Pluri Inc. | 22.48 Million USD | 57.218% |
| Prothena Corporation plc | 282.4 Million USD | 96.594% |
| Adaptimmune Therapeutics plc | 200.02 Million USD | 95.192% |
| Celularity Inc. | 215.05 Million USD | 95.528% |
| Rallybio Corporation | 78.93 Million USD | 87.816% |
| Cue Biopharma, Inc. | 19.54 Million USD | 50.786% |
| MeiraGTx Holdings plc | 151.07 Million USD | 93.634% |
| Omeros Corporation | 94.75 Million USD | 89.85% |
| Humacyte, Inc. | 23.49 Million USD | 59.07% |
| Immunocore Holdings plc | 308.04 Million USD | 96.878% |
| Cocrystal Pharma, Inc. | 3.39 Million USD | -183.698% |
| Cidara Therapeutics, Inc. | 86.86 Million USD | 88.928% |
| Blueprint Medicines Corporation | 722.86 Million USD | 98.67% |
| CalciMedica, Inc. | 21.81 Million USD | 55.918% |
| Cabaletta Bio, Inc. | 74.66 Million USD | 87.118% |
| Marinus Pharmaceuticals, Inc. | 160.54 Million USD | 94.009% |
| Scholar Rock Holding Corporation | 171.29 Million USD | 94.385% |
| Sana Biotechnology, Inc. | 294.94 Million USD | 96.739% |
| Pulmatrix, Inc. | 22.03 Million USD | 56.36% |
| Elicio Therapeutics, Inc. | 34.57 Million USD | 72.184% |
| Vigil Neuroscience, Inc. | 88.86 Million USD | 89.178% |
| Intellia Therapeutics, Inc. | 551.56 Million USD | 98.256% |
| Adlai Nortye Ltd. American Depositary Shares | 72.55 Million USD | 86.744% |
| Cytokinetics, Incorporated | 173.61 Million USD | 94.46% |
| Eloxx Pharmaceuticals, Inc. | 34.41 Million USD | 72.058% |
| Nutriband Inc. | 5.73 Million USD | -67.724% |
| Protara Therapeutics, Inc. | 43.61 Million USD | 77.948% |
| Vor Biopharma Inc. | 126.03 Million USD | 92.369% |
| Roivant Sciences Ltd. | 1.18 Billion USD | 99.191% |
| Evogene Ltd. | 27.79 Million USD | 65.393% |
| ProKidney Corp. | 151.52 Million USD | 93.653% |
| Applied Therapeutics, Inc. | 74.17 Million USD | 87.034% |
| Hoth Therapeutics, Inc. | 7.69 Million USD | -25.027% |
| BridgeBio Pharma, Inc. | 614.22 Million USD | 98.434% |
| CorMedix Inc. | 48.95 Million USD | 80.356% |
| BioLineRx Ltd. | 50.8 Million USD | 81.069% |
| Tango Therapeutics, Inc. | 150.7 Million USD | 93.618% |
| Galectin Therapeutics Inc. | 38.07 Million USD | 74.739% |
| Atai Life Sciences N.V. | 125.78 Million USD | 92.354% |
| Renovaro Biosciences Inc. | 81.63 Million USD | 88.22% |
| Aerovate Therapeutics, Inc. | 81.4 Million USD | 88.186% |
| Zentalis Pharmaceuticals, Inc. | 252.55 Million USD | 96.192% |
| Sagimet Biosciences Inc. | 32.74 Million USD | 70.625% |
| MediciNova, Inc. | 10.9 Million USD | 11.769% |
| Praxis Precision Medicines, Inc. | 128.82 Million USD | 92.534% |
| Cardio Diagnostics Holdings, Inc. | 7.25 Million USD | -32.479% |
| GeoVax Labs, Inc. | 6.02 Million USD | -59.699% |
| Axsome Therapeutics, Inc. | 476.36 Million USD | 97.981% |
| Biomea Fusion, Inc. | 126.13 Million USD | 92.375% |
| PTC Therapeutics, Inc. | 1.31 Billion USD | 99.267% |
| Mereo BioPharma Group plc | 35.84 Million USD | 73.167% |
| Cullinan Oncology, Inc. | 191.08 Million USD | 94.967% |
| Syndax Pharmaceuticals, Inc. | 229.95 Million USD | 95.818% |
| Absci Corporation | 73.66 Million USD | 86.945% |
| NRx Pharmaceuticals, Inc. | 27.58 Million USD | 65.132% |
| 4D Molecular Therapeutics, Inc. | 133.59 Million USD | 92.801% |
| Dyne Therapeutics, Inc. | 242.16 Million USD | 96.029% |
| Kiniksa Pharmaceuticals, Ltd. | 262.04 Million USD | 96.33% |
| Ventyx Biosciences, Inc. | 207.99 Million USD | 95.376% |
| Allakos Inc. | 196.05 Million USD | 95.095% |
| Imunon, Inc. | 20.31 Million USD | 52.648% |
| Fulcrum Therapeutics, Inc. | 113.46 Million USD | 91.524% |
| Corcept Therapeutics Incorporated | 368.61 Million USD | 97.391% |
| BioAtla, Inc. | 129.68 Million USD | 92.584% |
| NLS Pharmaceutics AG | 11.8 Million USD | 18.546% |
| Bio-Path Holdings, Inc. | 15.84 Million USD | 39.296% |
| Allogene Therapeutics, Inc. | 84.91 Million USD | 88.675% |
| Larimar Therapeutics, Inc. | 41.75 Million USD | 76.969% |
| XOMA Corporation | 46.46 Million USD | 79.301% |
| Kezar Life Sciences, Inc. | 111.17 Million USD | 91.349% |
| Cara Therapeutics, Inc. | 142.46 Million USD | 93.249% |
| aTyr Pharma, Inc. | 12.97 Million USD | 25.901% |
| Aligos Therapeutics, Inc. | 103.65 Million USD | 90.722% |
| Akero Therapeutics, Inc. | 172.87 Million USD | 94.437% |
| Viridian Therapeutics, Inc. | 254.76 Million USD | 96.225% |
| Eliem Therapeutics, Inc. | 37.4 Million USD | 74.291% |
| EyeGate Pharmaceuticals, Inc. | 8.22 Million USD | -16.931% |
| Akari Therapeutics, Plc | 16.8 Million USD | 42.774% |
| Tevogen Bio Holdings Inc. | 2.27 Million USD | -322.933% |
| Halozyme Therapeutics, Inc. | 299.31 Million USD | 96.787% |
| Lexaria Bioscience Corp. | 6.72 Million USD | -42.93% |
| UroGen Pharma Ltd. | 138.88 Million USD | 93.075% |
| Sutro Biopharma, Inc. | 243 Million USD | 96.042% |
| ZIVO Bioscience, Inc. | 7.27 Million USD | -32.204% |
| Orgenesis Inc. | 45.75 Million USD | 78.982% |
| Entera Bio Ltd. | 8.86 Million USD | -8.548% |
| GH Research PLC | 41.22 Million USD | 76.669% |
| Lisata Therapeutics, Inc. | 25.7 Million USD | 62.59% |
| Reneo Pharmaceuticals, Inc. | 83.05 Million USD | 88.42% |
| Xencor, Inc. | 306.97 Million USD | 96.867% |
| 60 Degrees Pharmaceuticals, Inc. | 4.93 Million USD | -94.936% |
| Replimune Group, Inc. | 234.77 Million USD | 95.904% |
| Coeptis Therapeutics Holdings, Inc. | 20.48 Million USD | 53.063% |
| Vanda Pharmaceuticals Inc. | 191.79 Million USD | 94.986% |
| Lexaria Bioscience Corp. | 6.72 Million USD | -42.93% |
| Portage Biotech Inc. | 18.19 Million USD | 47.154% |
| Cardio Diagnostics Holdings, Inc. | 7.25 Million USD | -32.479% |
| Olema Pharmaceuticals, Inc. | 104.96 Million USD | 90.837% |
| OncoCyte Corporation | 25.63 Million USD | 62.486% |
| Qualigen Therapeutics, Inc. | 6.09 Million USD | -57.775% |
| Processa Pharmaceuticals, Inc. | 11.45 Million USD | 16.057% |
| Purple Biotech Ltd. | -22.46 Million USD | 142.807% |
| CollPlant Biotechnologies Ltd. | 16.48 Million USD | 41.642% |
| scPharmaceuticals Inc. | 65.17 Million USD | 85.244% |
| ProMIS Neurosciences, Inc. | 8.45 Million USD | -13.778% |
| HilleVax, Inc. | 133.34 Million USD | 92.788% |
| NeuroSense Therapeutics Ltd. | 10.28 Million USD | 6.491% |
| Tharimmune, Inc. | 9.45 Million USD | -1.715% |
| Genprex, Inc. | 31.06 Million USD | 69.037% |
| Neumora Therapeutics, Inc. Common Stock | 187.52 Million USD | 94.871% |
| Atossa Therapeutics, Inc. | 31.37 Million USD | 69.349% |
| XTL Biopharmaceuticals Ltd. | 765 Thousand USD | -1157.172% |
| Virios Therapeutics, Inc. | 5.44 Million USD | -76.565% |
| OKYO Pharma Limited | 8243.57 USD | -116565.013% |
| Savara Inc. | 15.74 Million USD | 38.918% |
| Curis, Inc. | 58.35 Million USD | 83.519% |
| Daré Bioscience, Inc. | 33.6 Million USD | 71.385% |
| Carmell Therapeutics Corporation | 5.09 Million USD | -88.854% |
| Titan Pharmaceuticals, Inc. | 7.46 Million USD | -28.902% |
| Achieve Life Sciences, Inc. | 27.02 Million USD | 64.409% |
| BeiGene, Ltd. | 3.28 Billion USD | 99.707% |
| Kiromic BioPharma, Inc. | 19.93 Million USD | 51.767% |
| Revolution Medicines, Inc. Warrant | 498.76 Million USD | 98.072% |
| Protagonist Therapeutics, Inc. | 153.65 Million USD | 93.741% |
| Erasca, Inc. | 141.52 Million USD | 93.204% |
| bluebird bio, Inc. | 240.23 Million USD | 95.997% |
| Protagenic Therapeutics, Inc. | 4.52 Million USD | -112.446% |
| BioMarin Pharmaceutical Inc. | 1.74 Billion USD | 99.449% |
| DBV Technologies S.A. | 92.16 Million USD | 89.564% |
| Protagenic Therapeutics, Inc. | 4.52 Million USD | -112.446% |
| Moderna, Inc. | 6.39 Billion USD | 99.85% |
| Vincerx Pharma, Inc. | 42.6 Million USD | 77.429% |
| Fresh Tracks Therapeutics, Inc. | 14.36 Million USD | 33.055% |
| Molecular Templates, Inc. | 63.09 Million USD | 84.756% |
| Acrivon Therapeutics, Inc. Common Stock | 66.7 Million USD | 85.581% |
| Travere Therapeutics, Inc. | 472 Million USD | 97.962% |
| Monte Rosa Therapeutics, Inc. | 143.31 Million USD | 93.289% |
| Spruce Biosciences, Inc. | 62.08 Million USD | 84.509% |
| Celldex Therapeutics, Inc. | 43.41 Million USD | 77.847% |
| Cogent Biosciences, Inc. | 208.13 Million USD | 95.379% |
| MacroGenics, Inc. | 217.21 Million USD | 95.572% |
| RenovoRx, Inc. | 11.39 Million USD | 15.608% |
| Adicet Bio, Inc. | 152.03 Million USD | 93.674% |
| Prime Medicine, Inc. | 186.63 Million USD | 94.847% |
| Aditxt, Inc. | 25.95 Million USD | 62.94% |
| Adagene Inc. | 41.83 Million USD | 77.009% |
| Estrella Immunopharma, Inc. | 7.31 Million USD | -31.563% |
| Quantum-Si incorporated | 111.65 Million USD | 91.387% |
| Maravai LifeSciences Holdings, Inc. | 171.85 Million USD | 94.404% |
| Acurx Pharmaceuticals, Inc. | 14.57 Million USD | 34.027% |
| Voyager Therapeutics, Inc. | 35.82 Million USD | 73.152% |
| SciSparc Ltd. | 9.01 Million USD | -6.729% |
| Vericel Corporation | 142.04 Million USD | 93.229% |
| Revelation Biosciences, Inc. | 8.65 Million USD | -11.098% |
| Minerva Neurosciences, Inc. | 23.08 Million USD | 58.346% |
| Generation Bio Co. | 144.46 Million USD | 93.343% |
| Astria Therapeutics, Inc. | 83.03 Million USD | 88.417% |
| Black Diamond Therapeutics, Inc. | 86.46 Million USD | 88.877% |
| Arcutis Biotherapeutics, Inc. | 295.72 Million USD | 96.748% |
| Invivyd, Inc. | 205.75 Million USD | 95.326% |
| Relay Therapeutics, Inc. | 72.15 Million USD | 86.672% |
| Quoin Pharmaceuticals, Ltd. | 9.37 Million USD | -2.547% |
| Spero Therapeutics, Inc. | 75.25 Million USD | 87.22% |
| Artelo Biosciences, Inc. | 10.28 Million USD | 6.51% |
| 2seventy bio, Inc. | 289.88 Million USD | 96.682% |
| ADMA Biologics, Inc. | 66.58 Million USD | 85.556% |
| Clene Inc. | 41.07 Million USD | 76.585% |
| Capricor Therapeutics, Inc. | 12.8 Million USD | 24.911% |
| Boundless Bio, Inc. Common Stock | 54.79 Million USD | 82.449% |
| GeoVax Labs, Inc. | 6.02 Million USD | -59.699% |
| Recursion Pharmaceuticals, Inc. | 352.04 Million USD | 97.268% |
| Citius Pharmaceuticals, Inc. | 36.73 Million USD | 73.817% |
| Contineum Therapeutics, Inc. Class A Common Stock | 33.72 Million USD | 71.486% |
| Relmada Therapeutics, Inc. | 103.7 Million USD | 90.726% |
| Finch Therapeutics Group, Inc. | 32.58 Million USD | 70.489% |
| ALX Oncology Holdings Inc. | 170.27 Million USD | 94.352% |
| Vir Biotechnology, Inc. | 767.72 Million USD | 98.747% |
| Evaxion Biotech A/S | 22.27 Million USD | 56.815% |
| Ocular Therapeutix, Inc. | 135.54 Million USD | 92.905% |
| Verve Therapeutics, Inc. | 234.88 Million USD | 95.905% |
| Trevena, Inc. | 38.41 Million USD | 74.963% |
| Surrozen, Inc. | 18.55 Million USD | 48.154% |
| Tyra Biosciences, Inc. | 79.94 Million USD | 87.97% |
| Cingulate Inc. | 22.75 Million USD | 57.743% |
| Galmed Pharmaceuticals Ltd. | -7.49 Million USD | 228.368% |
| Unity Biotechnology, Inc. | 44.66 Million USD | 78.469% |
| Tenax Therapeutics, Inc. | 8.23 Million USD | -16.801% |
| Terns Pharmaceuticals, Inc. | 102.55 Million USD | 90.623% |
| ACADIA Pharmaceuticals Inc. | 754.08 Million USD | 98.725% |
| Connect Biopharma Holdings Limited | 62.07 Million USD | 84.507% |
| Clearmind Medicine Inc. | 8.74 Million USD | -10.021% |
| Kronos Bio, Inc. | 128.11 Million USD | 92.493% |
| Bolt Biotherapeutics, Inc. | 84.07 Million USD | 88.561% |
| CERo Therapeutics Holdings, Inc. | 2.93 Million USD | -227.904% |
| Viking Therapeutics, Inc. | 100.82 Million USD | 90.462% |
| Statera Biopharma, Inc. | 28.82 Million USD | 66.641% |
| ImmunityBio, Inc. | 362.87 Million USD | 97.35% |
| Korro Bio, Inc. | 84.53 Million USD | 88.623% |
| Kineta, Inc. | 21.15 Million USD | 54.541% |
| BioVie Inc. | 31.95 Million USD | 69.899% |
| Codexis, Inc. | 66.51 Million USD | 85.542% |
| Celularity Inc. | 215.05 Million USD | 95.528% |
| Crinetics Pharmaceuticals, Inc. | 226.62 Million USD | 95.756% |
| Celcuity Inc. | 66.23 Million USD | 85.479% |
| Virax Biolabs Group Limited | 6.54 Million USD | -46.896% |
| Cibus, Inc. | 320.3 Million USD | 96.997% |
| Eledon Pharmaceuticals, Inc. | 43 Million USD | 77.634% |
| eFFECTOR Therapeutics, Inc. | 33.84 Million USD | 71.583% |
| IN8bio, Inc. | 30.33 Million USD | 68.298% |
| Kodiak Sciences Inc. | 277.32 Million USD | 96.532% |
| Annexon, Inc. | 143.72 Million USD | 93.308% |
| Adverum Biotechnologies, Inc. | 127.59 Million USD | 92.462% |
| Assembly Biosciences, Inc. | 22.9 Million USD | 58.019% |
| Avalo Therapeutics, Inc. | 640 Thousand USD | -1402.713% |
| Ionis Pharmaceuticals, Inc. | 779.58 Million USD | 98.766% |
| Eyenovia, Inc. | 25.4 Million USD | 62.146% |
| Puma Biotechnology, Inc. | 140.31 Million USD | 93.146% |
| Conduit Pharmaceuticals Inc. | 5.56 Million USD | -72.912% |
| Xilio Therapeutics, Inc. | 79.13 Million USD | 87.847% |
| Arcellx, Inc. | 200.19 Million USD | 95.196% |
| Cardiff Oncology, Inc. | 45.9 Million USD | 79.047% |
| Enanta Pharmaceuticals, Inc. | 216.41 Million USD | 95.556% |
| Regulus Therapeutics Inc. | 9.95 Million USD | 3.411% |
| Moolec Science SA | 52.75 Million USD | 81.768% |
| Acumen Pharmaceuticals, Inc. | 61.13 Million USD | 84.269% |
| Geron Corporation | 70.44 Million USD | 86.347% |
| LAVA Therapeutics N.V. | 46.54 Million USD | 79.335% |
| Royalty Pharma plc | 862.4 Million USD | 98.885% |
| Atea Pharmaceuticals, Inc. | 94.07 Million USD | 89.777% |
| Greenwich LifeSciences, Inc. | 9.32 Million USD | -3.104% |
| TFF Pharmaceuticals, Inc. | 22.62 Million USD | 57.499% |
| Mersana Therapeutics, Inc. | 207.81 Million USD | 95.372% |
| Humacyte, Inc. | 23.49 Million USD | 59.07% |
| Structure Therapeutics Inc. | 102.77 Million USD | 90.642% |
| 89bio, Inc. | 151.2 Million USD | 93.639% |
| PMV Pharmaceuticals, Inc. | 80.13 Million USD | 87.998% |
| Avenue Therapeutics, Inc. | 14.54 Million USD | 33.856% |
| Genelux Corporation | 24.33 Million USD | 60.479% |
| Trevi Therapeutics, Inc. | 33.92 Million USD | 71.649% |
| Lexicon Pharmaceuticals, Inc. | 172.86 Million USD | 94.437% |
| Notable Labs, Ltd. | 14.77 Million USD | 34.886% |
| Liquidia Corporation | 87.98 Million USD | 89.069% |
| Mustang Bio, Inc. | 48.5 Million USD | 80.171% |
| Immunovant, Inc. | 282.7 Million USD | 96.598% |
| Quantum-Si incorporated | 111.65 Million USD | 91.387% |
| Arbutus Biopharma Corporation | 22.54 Million USD | 57.34% |
| DiaMedica Therapeutics Inc. | 21.26 Million USD | 54.778% |
| Vera Therapeutics, Inc. | 102.01 Million USD | 90.572% |
| Acasti Pharma Inc. | 11.3 Million USD | 14.898% |
| MiNK Therapeutics, Inc. | 22.92 Million USD | 58.041% |
| Pasithea Therapeutics Corp. | 15.97 Million USD | 39.814% |
| Xenon Pharmaceuticals Inc. | 46.54 Million USD | 79.336% |
| Elevai Labs, Inc. Common Stock | 1.13 Million USD | -747.658% |
| NeuroBo Pharmaceuticals, Inc. | 15.88 Million USD | 39.46% |
| Tempest Therapeutics, Inc. | 29.15 Million USD | 67.015% |
| Soleno Therapeutics, Inc. | 41.38 Million USD | 76.761% |
| PepGen Inc. | 84.76 Million USD | 88.654% |
| Moleculin Biotech, Inc. | 29.63 Million USD | 67.543% |
| United Therapeutics Corporation | 885.1 Million USD | 98.913% |
| Nuvectis Pharma, Inc. | 22.89 Million USD | 57.997% |
| Solid Biosciences Inc. | 104.31 Million USD | 90.78% |
| BriaCell Therapeutics Corp. | 32.72 Million USD | 70.612% |
| Immuneering Corporation | 58.41 Million USD | 83.536% |
| Lixte Biotechnology Holdings, Inc. | 5.09 Million USD | -88.937% |
| Silo Pharma, Inc. | 3.92 Million USD | -145.225% |
| Belite Bio, Inc | 31.66 Million USD | 69.631% |
| XOMA Corporation | 46.46 Million USD | 79.301% |
| ARS Pharmaceuticals, Inc. | 67.55 Million USD | 85.763% |
| Bionomics Limited | 17.89 Billion USD | 99.946% |
| Apogee Therapeutics, Inc. | 93 Million USD | 89.659% |
| Alpha Tau Medical Ltd. | -35.68 Million USD | 126.954% |
| uniQure N.V. | 285.08 Million USD | 96.627% |
| Cassava Sciences, Inc. | 105.95 Million USD | 90.923% |
| Estrella Immunopharma, Inc. | 7.31 Million USD | -31.563% |
| Poseida Therapeutics, Inc. | 194.2 Million USD | 95.048% |
| Forte Biosciences, Inc. | 32.47 Million USD | 70.387% |
| Anebulo Pharmaceuticals, Inc. | 8.3 Million USD | -15.75% |
| Enlivex Therapeutics Ltd. | 29.39 Million USD | 67.282% |
| Conduit Pharmaceuticals Inc. | 5.56 Million USD | -72.912% |
| SeaStar Medical Holding Corporation | 14.21 Million USD | 32.32% |
| FibroBiologics, Inc. Common Stock | 8.88 Million USD | -8.194% |
| Altimmune, Inc. | 30.55 Million USD | 68.525% |
| Amicus Therapeutics, Inc. | 427.65 Million USD | 97.751% |
| Alpha Tau Medical Ltd. | -35.68 Million USD | 126.954% |
| Compugen Ltd. | 43.97 Million USD | 78.128% |
| Peak Bio, Inc. | 1249.13 USD | -769824.828% |
| Zevra Therapeutics, Inc. | 74.12 Million USD | 87.025% |
| Benitec Biopharma Inc. | 22.38 Million USD | 57.031% |
| Spyre Therapeutics, Inc. | 243.18 Million USD | 96.045% |
| NKGen Biotech, Inc. Common Stock | 28.54 Million USD | 66.306% |
| Zura Bio Limited | 62.63 Million USD | 84.646% |
| PolyPid Ltd. | 21.04 Million USD | 54.301% |
| Aileron Therapeutics, Inc. | 16.27 Million USD | 40.911% |
| NKGen Biotech, Inc. Warrants | 28.54 Million USD | 66.306% |
| Instil Bio, Inc. | 85.78 Million USD | 88.789% |
| argenx SE | 1.53 Billion USD | 99.373% |
| Immunome, Inc. | 122.82 Million USD | 92.17% |
| Compass Therapeutics, Inc. | 48.47 Million USD | 80.159% |
| Verona Pharma plc | 67.15 Million USD | 85.678% |
| enGene Holdings Inc. Warrants | 25.88 Million USD | 62.846% |
| Shattuck Labs, Inc. | 93.61 Million USD | 89.727% |
| CervoMed Inc. | 14.95 Million USD | 35.703% |
| LENZ Therapeutics, Inc. | 70.7 Million USD | 86.398% |
| Plus Therapeutics, Inc. | 8.54 Million USD | -12.563% |
| Dianthus Therapeutics, Inc. | 51 Million USD | 81.142% |
| Moolec Science SA | 52.75 Million USD | 81.768% |
| Enveric Biosciences, Inc. | 16.44 Million USD | 41.53% |
| Inovio Pharmaceuticals, Inc. | 132.55 Million USD | 92.745% |
| AnaptysBio, Inc. | 181.56 Million USD | 94.703% |
| Design Therapeutics, Inc. | 78.19 Million USD | 87.7% |
| Leap Therapeutics, Inc. | 87.04 Million USD | 88.951% |
| NeurAxis, Inc. | 8.82 Million USD | -9.026% |
| Seelos Therapeutics, Inc. | 12.58 Million USD | 23.581% |
| Lumos Pharma, Inc. | 38.66 Million USD | 75.126% |
| Achilles Therapeutics plc | 75.25 Million USD | 87.22% |
| enGene Holdings Inc. Common Stock | 25.88 Million USD | 62.846% |
| 180 Life Sciences Corp. | 13.47 Million USD | 28.641% |
| Opiant Pharmaceuticals, Inc. | 26.5 Million USD | 63.711% |
| CERo Therapeutics Holdings, Inc. | 2.93 Million USD | -227.904% |
| Nutriband Inc. | 5.73 Million USD | -67.724% |
| ORIC Pharmaceuticals, Inc. | 110.78 Million USD | 91.319% |
| CG Oncology, Inc. Common stock | 55.65 Million USD | 82.719% |
| Fractyl Health, Inc. Common Stock | 50.87 Million USD | 81.098% |
| Rani Therapeutics Holdings, Inc. | 66.09 Million USD | 85.45% |
| MoonLake Immunotherapeutics | 54.12 Million USD | 82.231% |
| Palisade Bio, Inc. | 13.32 Million USD | 27.798% |
| Tourmaline Bio, Inc. | 45.4 Million USD | 78.821% |
| Beam Therapeutics Inc. | 554.19 Million USD | 98.265% |
| Neurogene Inc. | 55.58 Million USD | 82.697% |
| Mirum Pharmaceuticals, Inc. | 248.48 Million USD | 96.13% |
| AEON Biopharma, Inc. | 48.42 Million USD | 80.141% |
| CARGO Therapeutics, Inc. Common Stock | 96.71 Million USD | 90.055% |
| Sesen Bio, Inc. | 78.38 Million USD | 87.73% |
| Enliven Therapeutics, Inc. | 83.52 Million USD | 88.486% |
| Kiora Pharmaceuticals, Inc. | 12.58 Million USD | 23.592% |
| Iovance Biotherapeutics, Inc. | 450.99 Million USD | 97.868% |
| Taysha Gene Therapies, Inc. | 87.89 Million USD | 89.058% |
| Athira Pharma, Inc. | 125.46 Million USD | 92.335% |
| Vaccinex, Inc. | 23.45 Million USD | 58.997% |
| HCW Biologics Inc. | 21.02 Million USD | 54.263% |
| XOMA Corporation | 46.46 Million USD | 79.301% |
| Nektar Therapeutics | 190.9 Million USD | 94.962% |
| Arvinas, Inc. | 480 Million USD | 97.996% |
| Tevogen Bio Holdings Inc. | 2.27 Million USD | -322.933% |
| Merus N.V. | 200.49 Million USD | 95.203% |
| Omega Therapeutics, Inc. | 103.35 Million USD | 90.695% |
| Quince Therapeutics, Inc. | 34.62 Million USD | 72.22% |
| Rezolute, Inc. | 70.38 Million USD | 86.336% |
| Clene Inc. | 41.07 Million USD | 76.585% |
| Indaptus Therapeutics, Inc. | 16.37 Million USD | 41.28% |
| BeyondSpring Inc. | 24.86 Million USD | 61.322% |
| Synlogic, Inc. | 58.53 Million USD | 83.569% |
| Allarity Therapeutics, Inc. | 17.89 Million USD | 46.248% |
| Phio Pharmaceuticals Corp. | 4.49 Million USD | -114.1% |
| Peak Bio, Inc. | 1249.13 USD | -769824.828% |
| Werewolf Therapeutics, Inc. | 60.44 Million USD | 84.089% |
| Krystal Biotech, Inc. | 160.42 Million USD | 94.005% |
| Karyopharm Therapeutics Inc. | 270.63 Million USD | 96.446% |
| SpringWorks Therapeutics, Inc. | 348.03 Million USD | 97.237% |
| Lipella Pharmaceuticals Inc. | 2.15 Million USD | -345.922% |
| MannKind Corporation | 125.59 Million USD | 92.343% |
| Ikena Oncology, Inc. | 84.57 Million USD | 88.629% |
| Cyclerion Therapeutics, Inc. | 9.64 Million USD | 0.307% |
| Gyre Therapeutics, Inc. | 89.6 Million USD | 89.266% |
| Gossamer Bio, Inc. | 183.75 Million USD | 94.766% |
| CohBar, Inc. | 12.38 Million USD | 22.367% |
| Cognition Therapeutics, Inc. | 50.72 Million USD | 81.04% |
| NRx Pharmaceuticals, Inc. | 27.58 Million USD | 65.132% |
| Legend Biotech Corporation | 583.14 Million USD | 98.351% |
| Mural Oncology plc | 192.07 Million USD | 94.993% |
| Biora Therapeutics, Inc. | 67.14 Million USD | 85.677% |
| PaxMedica, Inc. Common Stock | 16.14 Million USD | 40.432% |
| Disc Medicine, Inc. | 91.12 Million USD | 89.446% |
| Champions Oncology, Inc. | 28.11 Million USD | 65.787% |
| REGENXBIO Inc. | 321.15 Million USD | 97.005% |
| Ensysce Biosciences, Inc. | 5.36 Million USD | -79.387% |
| Anavex Life Sciences Corp. | 55.75 Million USD | 82.751% |
| Cellectar Biosciences, Inc. | 38.96 Million USD | 75.315% |
| Edgewise Therapeutics, Inc. | 114.35 Million USD | 91.59% |
| Vaxart, Inc. | 90.72 Million USD | 89.4% |
| PharmaCyte Biotech, Inc. | 8.52 Million USD | -12.88% |
| Aldeyra Therapeutics, Inc. | 42.79 Million USD | 77.526% |
| Cellectis S.A. | 97.32 Million USD | 90.118% |
| Longeveron Inc. | 21.25 Million USD | 54.742% |
| Repare Therapeutics Inc. | 167.35 Million USD | 94.253% |
| Sarepta Therapeutics, Inc. | 1.36 Billion USD | 99.293% |
| Inozyme Pharma, Inc. | 75.64 Million USD | 87.286% |
| Revolution Medicines, Inc. | 498.76 Million USD | 98.072% |
| Nymox Pharmaceutical Corporation | 6.65 Million USD | -44.579% |
| Third Harmonic Bio, Inc. | 43.95 Million USD | 78.119% |
| ArriVent BioPharma, Inc. Common Stock | 74.59 Million USD | 87.106% |
| AN2 Therapeutics, Inc. | 69.63 Million USD | 86.189% |
| Anixa Biosciences, Inc. | 11.06 Million USD | 13.044% |
| Vertex Pharmaceuticals Incorporated | 4.77 Billion USD | 99.799% |
| Denali Therapeutics Inc. | 527.23 Million USD | 98.176% |
| Revelation Biosciences, Inc. | 8.65 Million USD | -11.098% |
| Veru Inc. | 101.34 Million USD | 90.511% |
| Corvus Pharmaceuticals, Inc. | 23.4 Million USD | 58.912% |
| Cingulate Inc. | 22.75 Million USD | 57.743% |
| Passage Bio, Inc. | 108.38 Million USD | 91.127% |
| Context Therapeutics Inc. | 25.07 Million USD | 61.642% |
| Exicure, Inc. | 14.07 Million USD | 31.675% |
| Day One Biopharmaceuticals, Inc. | 206.06 Million USD | 95.333% |
| Oramed Pharmaceuticals Inc. | 43.3 Million USD | 77.79% |
| Scinai Immunotherapeutics Ltd. | 9.17 Million USD | -4.795% |
| Rhythm Pharmaceuticals, Inc. | 252.48 Million USD | 96.191% |
| Nuvalent, Inc. | 149.49 Million USD | 93.567% |
| ABVC BioPharma, Inc. | 8.06 Million USD | -19.22% |
| Carisma Therapeutics, Inc. | 103.65 Million USD | 90.721% |
| Unicycive Therapeutics, Inc. | 21.44 Million USD | 55.162% |
| OmniAb, Inc. | 83.89 Million USD | 88.536% |
| Anew Medical, Inc. | 1.3 Million USD | -639.319% |
| Fennec Pharmaceuticals Inc. | 32.76 Million USD | 70.647% |
| Lipocine Inc. | 15.08 Million USD | 36.225% |
| Lexeo Therapeutics, Inc. Common Stock | 68.51 Million USD | 85.963% |
| Nautilus Biotechnology, Inc. | 76.15 Million USD | 87.371% |
| SAB Biotherapeutics, Inc. | 40.31 Million USD | 76.144% |
| G1 Therapeutics, Inc. | 114.84 Million USD | 91.626% |
| Bellerophon Therapeutics, Inc. | 22.38 Million USD | 57.035% |
| Sage Therapeutics, Inc. | 664.14 Million USD | 98.552% |
| Ocugen, Inc. | 71.56 Million USD | 86.562% |
| Mind Medicine (MindMed) Inc. | 93.86 Million USD | 89.754% |
| Q32 Bio Inc. | 92.68 Million USD | 89.623% |
| Brainstorm Cell Therapeutics Inc. | 21.17 Million USD | 54.579% |
| Alumis Inc. Common Stock | 158.17 Million USD | 93.92% |
| Equillium, Inc. | 50.6 Million USD | 80.996% |
| Kyverna Therapeutics, Inc. | 62.4 Million USD | 84.589% |
| Coya Therapeutics, Inc. | 13.9 Million USD | 30.838% |
| CNS Pharmaceuticals, Inc. | 18.86 Million USD | 49.02% |
| Galera Therapeutics, Inc. | 46.95 Million USD | 79.516% |
| Evelo Biosciences, Inc. | 108.46 Million USD | 91.133% |
| Comera Life Sciences Holdings, Inc. | 12.39 Million USD | 22.395% |
| Dominari Holdings Inc. | 23.83 Million USD | 59.65% |
| Edesa Biotech, Inc. | 9.22 Million USD | -4.279% |
| vTv Therapeutics Inc. | 11.9 Million USD | 19.229% |
| Bio-Techne Corporation | 563.03 Million USD | 98.292% |
| Agios Pharmaceuticals, Inc. | 408.8 Million USD | 97.647% |
| Harmony Biosciences Holdings, Inc. | 268.75 Million USD | 96.422% |
| Prelude Therapeutics Incorporated | 132.27 Million USD | 92.729% |
| Candel Therapeutics, Inc. | 14.41 Million USD | 33.264% |
| iTeos Therapeutics, Inc. | 163.69 Million USD | 94.125% |
| Nkarta, Inc. | 131.65 Million USD | 92.695% |
| BioCardia, Inc. | 12.12 Million USD | 20.655% |
| Iterum Therapeutics plc | 47.46 Million USD | 79.739% |